
MLYS Stock Forecast & Price Target
MLYS Analyst Ratings
Bulls say
Mineralys Therapeutics Inc. has demonstrated promising results from its clinical trials for lorundrostat, showing a robust placebo-adjusted reduction in blood pressure by 9.1 mmHg after six weeks and 11.7 mmHg after twelve weeks, indicating its potential effectiveness in treating uncontrolled and resistant hypertension. The favorable safety profile, with a low hyperkalemia rate of 1.1%, enhances the product's commercial viability and supports its differentiated position in the market. Given these encouraging outcomes and the potential for lorundrostat to achieve a significant blood pressure reduction of 8-12 mmHg, the outlook for Mineralys Therapeutics remains positive, suggesting substantial upside potential for the stock.
Bears say
Mineralys Therapeutics Inc. reported a significant net loss of $48.9 million for the fourth quarter of 2024 and a total net loss of $177.8 million for the full year, indicating substantial financial challenges. The company's investment outlook is burdened by critical risks, including the potential failure of its lead product candidate, lorundrostat, to meet projected peak commercial revenue due to limitations in market size, penetration rates, and pricing strategies. Additionally, there are concerns regarding the company's ability to secure sufficient capital to sustain operations and support ongoing program development and commercialization efforts.
This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MLYS Analyst Forecast & Price Prediction
Start investing in MLYS
Order type
Buy in
Order amount
Est. shares
0 shares